Press Releases

SALT LAKE CITY , Dec. 20, 2022 /PRNewswire/ --  Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:     41st Annual J.P.

Initiated our Phase 2 clinical trial for the potential treatment of familial adenomatous polyposis (FAP) Initiated our Phase 1 clinical trial for the potential treatment of  Clostridium difficile  colitis Nominated a new clinical program in  AXIN1 / APC  mutant cancers with an initial focus on

SALT LAKE CITY, Nov. 2, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences: Credit Suisse 31st Annual Healthcare Conference — 

SALT LAKE CITY , Oct. 25, 2022 / PRNewswire / -- Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced today that it has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million

Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiates a Phase 1 trial for the potential treatment of Clostridium difficile (C. diff) Colitis with Recursion's first new chemical entity to enter the clinic SALT

SALT LAKE CITY, Sept. 1, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences: Morgan Stanley Global Healthcare Conference —  September

SALT LAKE CITY, Aug. 18, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned  Institutional Shareholder

Actively enrolling participants in our Phase 2/3 clinical trial for the potential treatment of progressive NF2 -mutated meningiomas On track to initiate our Phase 2 clinical trial for the potential treatment of FAP in the third quarter of 2022 U.S. FDA granted Recursion Fast Track designation and

SALT LAKE CITY, Aug. 2, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference: KeyBanc Technology Leadership Forum —  August 8 through

SALT LAKE CITY, July 21, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the European Commission has granted Recursion Orphan Drug Designation for REC-4881 for the potential